[Skip to content]

Enter search here...

Area Prescribing


Worcestershire Area Prescribing Committee (APC) is a strategic decision-making committee of health care provider representatives across Worcestershire operating in a partnership capacity.  

The overall aim of the committee is to manage medicines usage across the Worcestershire health economy. This requires that the committee is pro-active with its health economy partners, taking a strategic approach by co-ordinating and directing policy across primary and secondary care, between Trusts and between clinical networks where possible.

The central principles of rational prescribing and medicines use, namely clinical and cost effectiveness, appropriateness (including convenience), safety, equitable provision of medicines and financial management, guide the thinking and outputs of the committee.


Central nervous system

Antiepileptic drugs: new advice on switching between different manufacturers’ products for a particular drug Nov 13
Antipsychotic Long-Acting Injection (Depot) Choice Pathway Nov 15
Attention Deficit Hyperactivity Disorder (ADHD) in Children, Adolescents and Adults: Prescribing Guideline Jul 17

Alzheimer's Dementia - Guidance for the treatment of  

Jan 12

Botulinum toxin - Position Statement

Jun 14   

Chronic Pain Guidelines

Jul 13
Co-proxamol position statement  Aug 16

Dementia (BPSD) - Guidelines for management of behavioural and psychological symptoms in patients in Primary Care/Care Homes

Dementia - Antipsychotics - Appendix 1 checklist

Jan 13

Dementia - Pain Prescribing Pathway      

Jun 14  
E-Cigarettes - smoking cessation; position statement
Feb 17
Generalised Anxiety Disorder (GAD) – Pharmacological Management  Nov 13
Firdapse Position Statment Jun 13
Lithium, Shared Care Guidelines Mar 17 
Melatonin Guidelines  Jan 14
Midazolam - Buccal product choice for Worcestershire Economy Mar 13
Neuropathic Pain, Guidelines for the Management of Aug 17
Quetiapine Modified Release
Nov 13
Restless Leg Syndrome (RLS) - Guidelines for the treatment of Jul 15
Sativex - Moderate to Severe Spasticity due to Multiple Sclerosis - Position Statement Nov,14  
Stopping Over-Medication of People with Learning Disabilities (STOMPLD) Jun 16
Targinact position statement  Aug 16
Tramacet position statement  Aug 16
Vortioxetine (Brintellix®) position statement – NICE TA 367 May 16 



Cancer & Immunosuppression


Stoma Management 

Stoma and Appliances Guidelines            

Jul 17


Ear, Nose & Oropharynx




Wound Management 

Wound Formulary                   

Feb 17


Palliative Care 

West Midlands Palliative Care guidelines 5th Edition 2012

Please refer to the Worcestershire Joint Medicines Formulary to confirm the formulary status of a specific medicine referred to within the guidance.        

Nov 13